Hills Bank & Trust Co Sells 498 Shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE)

Hills Bank & Trust Co cut its position in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) by 7.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,211 shares of the company’s stock after selling 498 shares during the quarter. Hills Bank & Trust Co owned approximately 0.15% of Invesco Biotechnology & Genome ETF worth $434,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of PBE. Commonwealth Equity Services LLC boosted its stake in shares of Invesco Biotechnology & Genome ETF by 1.9% in the 1st quarter. Commonwealth Equity Services LLC now owns 13,862 shares of the company’s stock valued at $897,000 after purchasing an additional 256 shares in the last quarter. US Bancorp DE grew its stake in shares of Invesco Biotechnology & Genome ETF by 1.8% during the first quarter. US Bancorp DE now owns 16,800 shares of the company’s stock valued at $1,087,000 after buying an additional 300 shares during the last quarter. Covestor Ltd increased its holdings in shares of Invesco Biotechnology & Genome ETF by 24.2% in the first quarter. Covestor Ltd now owns 955 shares of the company’s stock worth $62,000 after buying an additional 186 shares during the period. CreativeOne Wealth LLC increased its holdings in shares of Invesco Biotechnology & Genome ETF by 45.2% in the first quarter. CreativeOne Wealth LLC now owns 40,351 shares of the company’s stock worth $2,611,000 after buying an additional 12,564 shares during the period. Finally, B. Riley Wealth Advisors Inc. bought a new stake in shares of Invesco Biotechnology & Genome ETF in the 1st quarter valued at about $232,000.

Invesco Biotechnology & Genome ETF Price Performance

PBE opened at $69.14 on Friday. The stock’s 50 day simple moving average is $69.64 and its 200 day simple moving average is $66.97. The firm has a market cap of $279.33 million, a price-to-earnings ratio of 17.12 and a beta of 0.88. Invesco Biotechnology & Genome ETF has a 1 year low of $53.16 and a 1 year high of $72.72.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.